Peripheral blood-derived CD34+ stem cells for treatment of dilated cardiomyopathy

This study aims to test the safety and efficacy of intramyocardial CD34+ stem cell therapy as well as to compare the clinical effects of intramyocardial versus intracoronary CD34+ stem cell delivery methods in patients with dilated cardiomyopathy. During the 5-year follow-up period, cell therapy was associated with a significant improvement in cardiac function and exercise capacity and with a significant decrease in N-terminal brain natriuretic peptide levels.